Drugs / lademirsen
lademirsen
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03373786 | Dec 2017 → May 2019 | Alport syndrome | Genzyme, a Sanofi Company | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT02855268 | Nov 2019 → Sep 2022 | Alport syndrome | Genzyme, a Sanofi Company | Terminated | Missed primary |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | lademirsen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02855268 ↗ |
| Known as | RG-456070 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298087 ↗ |
| Known as | RG012 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03373786 ↗ |
| Known as | SAR339375 | “Study of Lademirsen (SAR339375) in Patients With Alport Syndrome” NCT02855268 ↗ |
| Action | Inhibit | “The objective of this study was to investigate the effects of the anti–miRNA-21 oligonucleotide, lademirsen, on rate of eGFR decline” PMID 38829703 ↗ Jun 2024 |
| Modality | Oligonucleotide (other) | “the anti–miRNA-21 oligonucleotide, lademirsen” PMID 38829703 ↗ Jun 2024 |
| Route | Subcutaneous | “1.5 mg/kg RG012 subcutaneous injection” NCT03373786 ↗ |